Skip to main content

Table 1 Summary of Changes in Lipid Profiles with Rheumatoid Arthritis Therapies

From: Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment

Study or Author RA drug Change in TC (mg/dL) Change in LDL-C (mg/dL) Change in HDL-C (mg/dL) Notes
Yamanaka et al. [171] TCZ ↑ 12.9 n/a n/a Concurrent DMARD use
Yazici et al. [172] TCZ ↑ 25.9 ↑ 17.8 ↑ 3.5 Concurrent DMARD use
Genovese et al. [103] TCZ ↑ 30.9 ↑ 3.8 ↑ 19.3 Concurrent DMARD use
Gabay et al. [161] TCZ ↑30.5 ↑20.1 ↑5.4 Change from baseline to week 8
Adalimumab ↑6.6 ↑2.7 ↑2.7
Tam et al. [173] Infliximab ↑23.2 ↑12.4 ↑5.8 Change from baseline to week 14
Kirkham et al. [174] Golimumab ↑8.0 ↑8.0 ↑3.0  
Morris et al. [175] Hydroxychloroquine ↓ 7.7 ↓ 7.6 ↑ 1.0  
Navarro-Millán et al. [176] Methotrexate with Etanercept ↑56.8 ↑31.4 ↑19.3 After 6 months of treatment
Triple therapya ↑53.0 ↑28.7 ↑22.3
Methotrexate ↑57.3 ↑30.0 ↑20.6
Charles-Schoeman et al. [177]b   ↑ week 24 ↑ week 24 ↑ week 24 Trend of lipids with treatment
↓week 102 ↓week 102 ↓week 102
Novikova et al. [178] Rituximab ↑19.7 ↑4.6 ↑12.0 After 6 months of treatment
  1. TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TCZ tocilizumab
  2. aTriple therapy=methotrexate plus sulfasalazine plus hydroxychloroquine, DMARD = disease modifying anti-rheumatic drugs
  3. bAbsolute numerical changes not available